Overview of the effectiveness of triple combination therapy in antiretroviral-naive HIV-1 infected adults

AIDS

Volumn 15, Issue 11, 2001, Pages 1369-1377

  Bartlett, John A ^a,d   DeMasi, Ralph ^b   Quinn, Joseph ^c   Moxham, Cary ^c   Rousseau, Franck ^c  

^a DUKE UNIVERSITY   (United States)

^b Trimeris Inc   (United States)

^c Triangle Pharmaceuticals   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Highly active antiretroviral therapy; HIV clinical trial; HIV RNA; Meta analysis; Viral load

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; META ANALYSIS; MULTIVARIATE ANALYSIS; PILL; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD;

CD4 LYMPHOCYTE COUNT; DRUG THERAPY, COMBINATION; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MULTIVARIATE ANALYSIS; REGRESSION ANALYSIS; REVERSE TRANSCRIPTASE INHIBITORS; VIRAL LOAD;

EID: 0035958773     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200107270-00006     Document Type: Article

References (37)

1. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma
2. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection
3. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter
4. Changes in plasma HIV-1 RNA and CD4+-lymphocyte counts and the risk of progression to AIDS
5. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection
6. Joint effects of HIV-1 RNA levels and CD4 lymphocyte cells on the risk of specific opportunistic infections
7. Panel on clinical practices for treatment of HIV Infection, covened by the Department of Health and Human Services (DHHS) and the Henry J. Kaiser Family Foundation
8. Antiretroviral therapy in adults, updated recommendations of the International AIDS Society - USA Panel
9. Detectable HIV-1 RNA at levels below quantifiable limits by Amplicor HIV-1 Monitor is associated with virologic relapse on antiretroviral therapy
10. Finding the truth: A guide to interpreting HIV clinical trials
11. Analysis of HIV-1 clinical trials: Statistical magic?
12. Comparison of a triple regimen containing once-daily diclanosine versus a regimen of zidovudine plus lamivudine plus nelfinavir
13. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients
14. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor (PI)-sparing antiretroviral strategies versus a standard PI-containing regimen, 48 week data
15. AVANTI-2. A randomized, double-blind trial to evaluate combination trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HW-infected antiretroviral naive patients
16. 10 reduction in clinical trials
17. Ziagen (abacavir, ABC, 1592] combined with 3TC & ZDV is highly effective and durable through 48 weeks in HIV-1 infected antiretroviral-therapy-naive subjects (CNAA3003)
18. A randomized double-blind equivalence trial comparing triple nucleoside therapy of abacavir, lamivudine, and zidovudine in antiretroviral naive adults
19. Preliminary results of a randomized multicenter study comparing combivir (ZDV/3TC) plus nelfinavir or nevirapine in HIV-Infected Naive Patients (COMBINE Study)
20. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine plus lamivudine in the treatment of HIV-1 infection in adults
21. Durability of response of efavirenz (Sustiva™, EFV)-containing regimens: Report of the post-control period results of studies with EFV
22. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, Sustiva™, DMP 266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) at 36 weeks [DMP 266-005]
23. A phase II, double-blind, placebo-controlled, dose-ranging study to assess the antiretroviral activity and safety of efavirenz (EFV, Sustiva, DMP266) in combination with open-label zidovudine (ZDV) and lamivudine (3TC) at > 48 weeks [DMP266-005]
24. Efavirenz is well tolerated and highly efficaious in combination with the nucleosides stavudine (d4T) J didanosine (ddl) or d4T + lamivudine (3TC)
25. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: The INCAS trial
26. ABT-378/ritonavir (ABT-378/r) in antiretroviral-naive HIV+ patients: 72 weeks
27. Second placebo-controlled study in naive individuals confirms the role of delavirdine in highly active antiretroviral, protease-sparing treatment
28. A phase II, open-label study to evaluate the antiviral activity, safety, and tolerability of emivirine (EMV, MKC-442) with stavudine (d4T) + didanosine (ddl)
29. Antiviral activity, safety, and tolerability of emivirine (EMV, Coactinon™) + stavudine (d4T, Zent™) + lamivudine (3TC, Epivir™) in treatment-naive HIV-infected volunteers (MKC-301)
30. Stavudine plus didanosine and nevirapine in antiretroviral naive HIV-infected adults: Preliminary safety and efficacy results
31. Predictive value of response at 12 and 24 weeks for durability of response in a study of the soft gelatin capsule formulation of saquinavir (SQV-SGC) plus 2 nucleosides in treatment-naive HIV-1-positive patients
32. Amprenavir (141W94, APV)/3TC/ZDV exerts durable antiviral activity in HIV-1-infected antiretroviral therapy-naive subjects through 48 weeks of therapy
33. An open-label, randomized, comparative study of stavudine (d4T) + lamivudine (3TC) + indinavir (IDV) versus zidovudine (ZDV) 3TC + IDV in treatment of HIV-infected patients: START I
34. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naïve individuals with HIV infection: Selection of thymidine analog regimen therapy (START I)
35. A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: Selection of thymidine analog regimen therapy (START II)
36. d4T + qd ddl + nevirapine (bid or qd) in antiretroviral-naive HIV-1-infected patients:1-year results of the VIRGO study